US regulatory status: approved.
pharma · Acne Vulgaris · Pruritus · VYNE
VYNE Therapeutics
VYNE Therapeutics drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
- Status
- Public
- HQ
- 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
- Founded
- 2003
- Employees
- 47
- Programs
- 30
- Drugs
- 16
- Patents
- 7
VYNE Therapeutics pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
VYNE Therapeutics drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
US regulatory status: approved. Molecular target: Voltage-sensitive sodium channel.
- Target
- Voltage-sensitive sodium channel
- Mechanism
- Voltage-sensitive sodium channel blocker
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
Development asset linked to VYNE Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist